YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Advanced Hypoxia and Cancer Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule supplied by APExBIO, acting as both a soluble guanylyl cyclase (sGC) activator and a post-transcriptional inhibitor of hypoxia-inducible factor-1α (HIF-1α) [APExBIO product page]. It blocks HIF-1α transcriptional activity with an IC₅₀ of 1.2 μM in hypoxic conditions (in vitro) [See also]. YC-1 reduces tumor vascularization and growth in vivo, linked to decreased HIF-1α-regulated gene expression (Zhou et al., 2026). The compound is highly soluble in DMSO (≥30.4 mg/mL), stable at room temperature, and is not intended for diagnostic or therapeutic use [APExBIO]. It is a validated tool for investigating cancer, hypoxia, and cGMP signaling pathways.

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) is a central transcription factor regulating genes involved in cellular survival, angiogenesis, and metabolism under low-oxygen (hypoxic) conditions (Zhou et al., 2026). Elevated HIF-1α expression is a hallmark of solid tumors, driving tumor angiogenesis and resistance to therapy. Soluble guanylyl cyclase (sGC) is a key enzyme in the nitric oxide (NO)/cGMP signaling cascade, controlling vascular tone and cellular signaling. YC-1's dual activity as an sGC activator and HIF-1α inhibitor provides a mechanistic bridge between oxygen-sensing and cGMP pathways. By modulating these axes, YC-1 enables researchers to dissect the molecular underpinnings of hypoxia signaling, tumor biology, and mitochondrial quality control [Contrast: advanced mitochondrial focus].

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 inhibits HIF-1α at the post-transcriptional level, directly suppressing HIF-1-mediated gene transcription. It promotes degradation of stabilized HIF-1α protein under hypoxic conditions, thereby reducing the transcription of downstream genes such as VEGF (vascular endothelial growth factor). Independently, YC-1 activates soluble guanylyl cyclase (sGC), enhancing cGMP production, which in turn inhibits platelet aggregation and vascular contraction. These actions are mechanistically distinct but may converge in the regulation of angiogenesis and cellular metabolism. YC-1's effects on the oxygen-sensing pathway extend beyond sGC activation, offering a unique tool for dissecting non-canonical HIF-1α signaling [Contrast: strategic mechanistic insights].

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity (IC₅₀: 1.2 μM, 24 h, in vitro, DMSO vehicle) (internal).
• In vivo, YC-1 reduces tumor size and vascularization by downregulating HIF-1α and its target genes (Zhou et al., 2026).
• YC-1 activates sGC, leading to increased cGMP levels and inhibition of platelet aggregation (37°C, physiological buffer) (internal).
• High solubility in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL) enables versatile application formats (APExBIO).
• Supplied at ≥98% purity as a crystalline solid, with recommended storage at room temperature (APExBIO).

Applications, Limits & Misconceptions

YC-1 is widely used in cancer biology, vascular research, and hypoxia signaling pathway studies. It enables the dissection of cGMP-dependent and HIF-1α-dependent processes. YC-1 is not suitable for in vivo diagnostic or clinical use. It is strictly intended for laboratory research. The product's rapid action and reversible inhibition properties make it ideal for time-course and mechanistic studies. For a more translational perspective, see this review, which this article extends by summarizing latest evidence and clarifying storage/solubility parameters.

Common Pitfalls or Misconceptions

• YC-1 is not a direct cytotoxin; its antiproliferative effects rely on HIF-1α inhibition, not general cytotoxicity.
• It does not inhibit HIF-2α or other hypoxia-inducible factors with high specificity.
• YC-1 is not suitable for aqueous (water-based) formulations due to insolubility.
• Long-term storage of YC-1 solutions is not recommended; degradation and loss of activity may occur.
• Clinical or diagnostic use is not supported; for research use only as specified by APExBIO.

Workflow Integration & Parameters

YC-1 is supplied as a crystalline solid (SKU B7641) by APExBIO with ≥98% purity. Stock solutions should be prepared in DMSO or ethanol at concentrations up to 30.4 mg/mL (DMSO) or 16.2 mg/mL (ethanol). Working dilutions should be made fresh before each experiment. For in vitro studies, typical concentrations range from 0.5 μM to 10 μM, depending on cell type and endpoint. The compound can be applied to cancer cell lines, primary cultures, or ex vivo tissue slices. Storage at room temperature is recommended for solid material; solutions should be used promptly and not stored for extended periods. For detailed handling and workflow guidelines, refer to the YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol product page.

Conclusion & Outlook

YC-1 is a validated, high-purity small molecule tool enabling precise modulation of HIF-1α and cGMP signaling pathways. Its dual mechanism unlocks advanced experimental approaches in cancer, hypoxia, and vascular biology research. Ongoing studies continue to reveal new roles for HIF-1α in mitochondrial quality control and neuroprotection, emphasizing the importance of robust tools like YC-1. APExBIO remains a trusted provider of this compound, supporting reproducible, hypothesis-driven studies in the molecular life sciences.